Trial · NCT03828799
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Pre-specified Treatment-related Adverse Events | Experimental: Irinotecan 150 mg/m² and Regorafenib 120 mg | 3 | participants | ||
| Number of Participants With Pre-specified Treatment-related Adverse Events | Experimental : Irinotecan 180 mg/m² and Regorafenib 120 mg | 5 | participants | ||
| Number of Participants With Pre-specified Treatment-related Adverse Events | Experimental : Irinotecan 180 mg/m² and Regorafenib 160 mg | 3 | participants | ||
| Progression-free Survival (PFS) | Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO) | 12.5 | Full Range 8.7 to 15.4 | Month | |
| Progression-free Survival (PFS) | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 120 mg (PO) | 8.2 | Full Range 3.1 to 9.1 | Month | |
| Progression-free Survival (PFS) | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO) | 5.1 | Full Range 3.4 to 7.7 | Month | |
| Number of Patients With Disease Control | Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO) | 3 | Participants | ||
| Number of Patients With Disease Control | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 120 mg (PO) | 6 | Participants | ||
| Number of Patients With Disease Control | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO) | 4 | Participants | ||
| Number of Participants With Objective Response | Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO) | 2 | participants | ||
| Number of Participants With Objective Response | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 120 mg (PO) | 3 | participants | ||
| Number of Participants With Objective Response | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO) | 4 | participants | ||
| Overall Survival (OS) | Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO) | 16.7 | Full Range 15.6 to 18 | Month | |
| Overall Survival (OS) | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 120 mg (PO) | 13.3 | Full Range 7 to 20 | Month | |
| Overall Survival (OS) | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO) | 10.7 | Full Range 7.2 to 15 | Month | |
| The Median of Regression of Tumor Size | Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO) | 55.3 | Full Range 21.7 to 64.7 | Percentage | |
| The Median of Regression of Tumor Size | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 120 mg (PO) | 40.85 | Full Range 1.1 to 61.7 | Percentage | |
| The Median of Regression of Tumor Size | Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO) | 60.75 | Full Range 40.6 to 73 | Percentage | |
| Maintenance Treatment With Regorafenib Alone | Folfirinox-R | Step 1 : IRINOTECAN 150 / REGORAFENIB 120 / 2 cycles received | 0 | Participants | |
| Maintenance Treatment With Regorafenib Alone | Folfirinox-R | Step 1 : IRINOTECAN 150 / REGORAFENIB 120 / 3 cycles received | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03828799/results